-
Tytuł:
-
Patterns in metabolite profile are associated with risk of more aggressive prostate cancer: A prospective study of 3,057 matched case-control sets from EPIC.
-
Autorzy:
-
Schmidt JA; Cancer Epidemiology Unit, Nuffield Department of Population Health, University of Oxford, Oxford, United Kingdom.
Fensom GK; Cancer Epidemiology Unit, Nuffield Department of Population Health, University of Oxford, Oxford, United Kingdom.
Rinaldi S; International Agency for Research on Cancer, Lyon, France.
Scalbert A; International Agency for Research on Cancer, Lyon, France.
Appleby PN; Cancer Epidemiology Unit, Nuffield Department of Population Health, University of Oxford, Oxford, United Kingdom.
Achaintre D; International Agency for Research on Cancer, Lyon, France.
Gicquiau A; International Agency for Research on Cancer, Lyon, France.
Gunter MJ; International Agency for Research on Cancer, Lyon, France.
Ferrari P; International Agency for Research on Cancer, Lyon, France.
Kaaks R; Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Kühn T; Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Boeing H; Department of Epidemiology, German Institute of Human Nutrition (DIfE) Potsdam-Rehbrücke, Nuthetal, Germany.
Trichopoulou A; Hellenic Health Foundation, Athens, Greece.
Karakatsani A; Hellenic Health Foundation, Athens, Greece.; 2nd Pulmonary Medicine Department, School of Medicine, National and Kapodistrian University of Athens, 'ATTIKON' University Hospital, Haidari, Greece.
Peppa E; Hellenic Health Foundation, Athens, Greece.
Palli D; Cancer Risk Factors and Life-Style Epidemiology Unit, Institute for Cancer Research, Prevention and Clinical Network (ISPRO), Florence, Italy.
Sieri S; Epidemiology and Prevention Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy.
Tumino R; Cancer Registry and Histopathology Department, 'Civic - M.P.Arezzo' Hospital, Azienda Sanitaria Provinciale Di Ragusa (ASP), Ragusa, Italy.
Bueno-de-Mesquita B; Department for Determinants of Chronic Diseases (DCD), National Institute for Public Health and the Environment (RIVM), Bilthoven, The Netherlands.; Department of Gastroenterology and Hepatology, University Medical Centre, Utrecht, The Netherlands.; Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London, London, United Kingdom.; Department of Social & Preventive Medicine, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia.
Agudo A; Unit of Nutrition and Cancer, Cancer Epidemiology Research Program, Catalan Institute of Oncology-IDIBELL, L'Hospitalet de Llobregat, Barcelona, Spain.
Sánchez MJ; CIBER in Epidemiology and Public Health (CIBERESP), Madrid, Spain.; Escuela Andaluza de Salud Pública, Instituto de Investigación Biosanitaria ibs.GRANADA, Hospitales Universitarios de Granada/Universidad de Granada, Granada, Spain.
Chirlaque MD; CIBER in Epidemiology and Public Health (CIBERESP), Madrid, Spain.; Department of Epidemiology, Regional Health Council, IMIB-Arrixaca, Murcia, Spain.; Department of Health and Social Sciences, Murcia University, Murcia, Spain.
Ardanaz E; CIBER in Epidemiology and Public Health (CIBERESP), Madrid, Spain.; Navarra Public Health Institute, Pamplona, Spain.; IdiSNA, Navarra Institute for Health Research, Pamplona, Spain.
Larrañaga N; CIBER in Epidemiology and Public Health (CIBERESP), Madrid, Spain.; Basque Regional Health Department, Public Health Division of Gipuzkoa-BIODONOSTIA, San Sebastian, Spain.
Perez-Cornago A; Cancer Epidemiology Unit, Nuffield Department of Population Health, University of Oxford, Oxford, United Kingdom.
Assi N; International Agency for Research on Cancer, Lyon, France.
Riboli E; Department of Hygiene and Epidemiology, University of Ioannina School of Medicine, Ioannina, Greece.
Tsilidis KK; Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London, London, United Kingdom.; Department of Hygiene and Epidemiology, University of Ioannina School of Medicine, Ioannina, Greece.
Key TJ; Cancer Epidemiology Unit, Nuffield Department of Population Health, University of Oxford, Oxford, United Kingdom.
Travis RC; Cancer Epidemiology Unit, Nuffield Department of Population Health, University of Oxford, Oxford, United Kingdom.
-
Źródło:
-
International journal of cancer [Int J Cancer] 2020 Feb 01; Vol. 146 (3), pp. 720-730. Date of Electronic Publication: 2019 Apr 29.
-
Typ publikacji:
-
Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
-
Język:
-
English
-
Imprint Name(s):
-
Publication: 1995- : New York, NY : Wiley-Liss
Original Publication: 1966-1984 : Genève : International Union Against Cancer
-
MeSH Terms:
-
Biomarkers, Tumor/*blood
Prostatic Neoplasms/*pathology
Aged ; Biomarkers, Tumor/metabolism ; Case-Control Studies ; Follow-Up Studies ; Humans ; Male ; Metabolomics ; Middle Aged ; Neoplasm Staging ; Nutrition Assessment ; Phosphatidylcholines/blood ; Phosphatidylcholines/metabolism ; Prospective Studies ; Prostate/pathology ; Prostatic Neoplasms/blood ; Prostatic Neoplasms/metabolism ; Risk Factors ; Sphingomyelins/blood ; Sphingomyelins/metabolism
-
References:
-
Cancer Epidemiol Biomarkers Prev. 2016 May;25(5):823-829. (PMID: 26941367)
Cancer Epidemiol Biomarkers Prev. 2016 Jun;25(6):887-906. (PMID: 27197278)
Am J Clin Nutr. 2015 Jun;101(6):1241-50. (PMID: 25948672)
Cancer Epidemiol Biomarkers Prev. 2013 Apr;22(4):631-40. (PMID: 23396963)
Metabolomics. 2014 Oct 1;10(5):1036-1041. (PMID: 25254003)
Oncotarget. 2017 Jul 11;8(28):45190-45199. (PMID: 28423352)
Front Oncol. 2016 Dec 27;6:266. (PMID: 28083512)
Public Health Nutr. 2016 Feb;19(2):242-54. (PMID: 25702596)
Am J Clin Nutr. 2012 Dec;96(6):1354-61. (PMID: 23134890)
Am J Clin Nutr. 2017 Aug;106(2):637-649. (PMID: 28659298)
Int J Obes (Lond). 2014 Nov;38(11):1388-96. (PMID: 24608922)
BMC Med. 2015 Sep 23;13:242. (PMID: 26399231)
Clin Chem. 2013 Nov;59(11):1657-67. (PMID: 23897902)
Transl Oncol. 2016 Aug;9(4):357-70. (PMID: 27567960)
PLoS One. 2015 Aug 14;10(8):e0135437. (PMID: 26274920)
Mol Nutr Food Res. 2015 Jul;59(7):1353-63. (PMID: 25787113)
PLoS One. 2011;6(6):e21103. (PMID: 21698256)
Am J Epidemiol. 2011 May 15;173(10):1097-104. (PMID: 21474587)
Environ Mol Mutagen. 2013 Aug;54(7):542-57. (PMID: 23918146)
BMC Med. 2016 Jan 28;14:13. (PMID: 26817443)
Eur J Clin Nutr. 2016 Mar;70(3):306-12. (PMID: 26395436)
Int J Cancer. 2018 Aug 1;143(3):527-534. (PMID: 29479691)
Int J Cancer. 2015 Nov 1;137(9):2124-32. (PMID: 25904191)
Chem Soc Rev. 2011 Jan;40(1):387-426. (PMID: 20717559)
Br J Cancer. 2016 Oct 25;115(9):1087-1095. (PMID: 27673363)
Public Health Nutr. 2002 Dec;5(6B):1113-24. (PMID: 12639222)
Int J Cancer. 2019 Dec 15;145(12):3231-3243. (PMID: 30779128)
Cancer Prev Res (Phila). 2018 May;11(5):303-312. (PMID: 29500188)
Am J Clin Nutr. 2015 Dec;102(6):1518-26. (PMID: 26511225)
Metabolism. 2015 Oct;64(10):1348-58. (PMID: 26271139)
BMC Med. 2017 Jul 5;15(1):122. (PMID: 28676103)
J Proteome Res. 2017 Sep 1;16(9):3137-3146. (PMID: 28758405)
Biochim Biophys Acta. 2014 May;1841(5):692-703. (PMID: 24355909)
Int J Cancer. 2018 Nov 1;143(9):2161-2167. (PMID: 29717485)
Cancer Epidemiol Biomarkers Prev. 2019 Jan;28(1):208-216. (PMID: 30352818)
Nutrients. 2018 May 22;10(5):null. (PMID: 29789452)
Metabolomics. 2009 Dec;5(4):435-458. (PMID: 20046865)
Int J Epidemiol. 2018 Apr 1;47(2):484-494. (PMID: 29365091)
Nutr J. 2013 Dec 11;12:158. (PMID: 24330454)
Nat Commun. 2016 Mar 23;7:11122. (PMID: 27005778)
Am J Clin Nutr. 2015 Oct;102(4):905-13. (PMID: 26269369)
Crit Rev Biochem Mol Biol. 2013 Jan-Feb;48(1):20-38. (PMID: 23350810)
-
Grant Information:
-
1000143 United Kingdom MRC_ Medical Research Council; 19170 United Kingdom CRUK_ Cancer Research UK; MR/N003284/1 United Kingdom MRC_ Medical Research Council; MR/M012190/1 United Kingdom MRC_ Medical Research Council; G0401527 United Kingdom MRC_ Medical Research Council; G1000143 United Kingdom MRC_ Medical Research Council; 14136 United Kingdom CRUK_ Cancer Research UK; C570/A16491 United Kingdom CRUK_ Cancer Research UK; 001 International WHO_ World Health Organization; 29017 United Kingdom CRUK_ Cancer Research UK; C8221/A19170 United Kingdom CRUK_ Cancer Research UK
-
Contributed Indexing:
-
Keywords: epidemiology; metabolomics; prostate cancer risk; treelet transform
-
Substance Nomenclature:
-
0 (Biomarkers, Tumor)
0 (Phosphatidylcholines)
0 (Sphingomyelins)
-
Entry Date(s):
-
Date Created: 20190406 Date Completed: 20200211 Latest Revision: 20240324
-
Update Code:
-
20240324
-
PubMed Central ID:
-
PMC6916595
-
DOI:
-
10.1002/ijc.32314
-
PMID:
-
30951192
-
Metabolomics may reveal novel insights into the etiology of prostate cancer, for which few risk factors are established. We investigated the association between patterns in baseline plasma metabolite profile and subsequent prostate cancer risk, using data from 3,057 matched case-control sets from the European Prospective Investigation into Cancer and Nutrition (EPIC). We measured 119 metabolite concentrations in plasma samples, collected on average 9.4 years before diagnosis, by mass spectrometry (AbsoluteIDQ p180 Kit, Biocrates Life Sciences AG). Metabolite patterns were identified using treelet transform, a statistical method for identification of groups of correlated metabolites. Associations of metabolite patterns with prostate cancer risk (OR 1SD ) were estimated by conditional logistic regression. Supplementary analyses were conducted for metabolite patterns derived using principal component analysis and for individual metabolites. Men with metabolite profiles characterized by higher concentrations of either phosphatidylcholines or hydroxysphingomyelins (OR 1SD = 0.77, 95% confidence interval 0.66-0.89), acylcarnitines C18:1 and C18:2, glutamate, ornithine and taurine (OR 1SD = 0.72, 0.57-0.90), or lysophosphatidylcholines (OR 1SD = 0.81, 0.69-0.95) had lower risk of advanced stage prostate cancer at diagnosis, with no evidence of heterogeneity by follow-up time. Similar associations were observed for the two former patterns with aggressive disease risk (the more aggressive subset of advanced stage), while the latter pattern was inversely related to risk of prostate cancer death (OR 1SD = 0.77, 0.61-0.96). No associations were observed for prostate cancer overall or less aggressive tumor subtypes. In conclusion, metabolite patterns may be related to lower risk of more aggressive prostate tumors and prostate cancer death, and might be relevant to etiology of advanced stage prostate cancer.
(© 2019 The Authors. International Journal of Cancer published by John Wiley & Sons Ltd on behalf of UICC.)
